Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcom...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Versluis, Jurjen, Labopin, Myriam, Ruggeri, Annalisa, Socie, Gerard, Wu, Depei, Volin, Liisa, Blaise, Didier, Milpied, Noel, Craddock, Charles, Yakoub-Agha, Ibrahim, Maertens, Johan, Ljungman, Per, Huynh, Anne, Michallet, Mauricette, Deconinck, Eric, Chevallier, Patrice, Passweg, Jakob, Ciceri, Fabio, Mohty, Mohamad, Cornelissen, Jan J., Nagler, Arnon
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Transplantation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738980/
https://ncbi.nlm.nih.gov/pubmed/29296964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016002386
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki